R Fleischmann
Impact in
- Rheumatology top 2%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments
-
- Biosimilars and Bioanalytical Methods
Papers in
- Rheumatology 19
- Rheumatoid Arthritis Research and Therapies 17
- Osteoarthritis Treatment and Mechanisms 2
- Spondyloarthritis Studies and Treatments 2
-
- Inflammatory mediators and NSAID effects 2
- Co-authors
- Gerd Rüdiger Burmester (2 shared papers)Lifen Zhou (1 shared paper)Paul E. Emery (5 shared papers)Edward Clark Keystone (2 shared papers)Philip J. Mease (3 shared papers)Bruce W Kirkham (1 shared paper)Nora G. Singer (1 shared paper)A. Gibofsky (1 shared paper)
- Journals
- Annals of the Rheumatic Diseases (3 papers)Lara D. Veeken (2 papers)Value in Health (1 paper)Transfusion (1 paper)Arthritis & Rheumatism (4 papers)
- Partner nations
- United StatesGermanyCanada
In The Last Decade
R Fleischmann
20 papers receiving 683 citations
Peers
Comparison fields: 5 of 64
- Rheumatology 392
- Immunology 75
- Hematology 37
- Infectious Diseases 37
- Oncology 39
Countries citing papers authored by R Fleischmann
This map shows the geographic impact of R Fleischmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Fleischmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Fleischmann more than expected).
Fields of papers citing papers by R Fleischmann
This network shows the impact of papers produced by R Fleischmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Fleischmann. The network helps show where R Fleischmann may publish in the future.
Co-authors
The 25 scholars most cited alongside R Fleischmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 347 | |
| 2 | 2006 | 261 | |
| 3 | A PHASE III TRIAL OF ETANERCEPT vs METHOTREXATE (MTX) IN EARLY RHEUMATOID ARTHRITIS (ENBREL ERA TRIAL) | 2000 | 34 |
| 4 | Clinical efficacy and safety of nabumetone in rheumatoid arthritis and osteoarthritis. | 1992 | 16 |
| 5 | Safety and tolerability of rituximab in patients with moderate to severe rheumatoid arthritis: Results from the dose-ranging assessment international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) study | 2005 | 13 |
| 6 | Treatment of rheumatoid arthritis with a DR4/1 peptide. | 2000 | 11 |
| 7 | 1991 | 10 | |
| 8 | Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis | 2005 | 9 |
| 9 | Golimumab, a new human Anti-TNF-alpha monoclonal antibody, administered subcutaneously everv 4 weeks in methotrexate-naive patients with active rheumatoid arthritis: A randomized, double-blind, placebo-controlled, GO-BEFORE study | 2008 | 4 |
| 10 | Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study | 2012 | 4 |
| 11 | EFFECT OF CERTOLIZUMAB PEGOL ON SIGNS AND SYMPTOMS IN PATIENTS WITH PSORIATIC ARTHRITIS WITH OR WITHOUT PRIOR ANTI-TNF EXPOSURE : 24-WEEK RESULTS OF A PHASE III DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY | 2013 | 4 |
| 12 | 2015 | 4 | |
| 13 | Priapism as a manifestation of isolated genital vasculitis. | 1991 | 3 |
| 14 | Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study | 2011 | 2 |
| 15 | 2012 | 2 | |
| 16 | 2013 | 2 | |
| 17 | The long-term U.S. study--a report on outcome and tolerance. | 1991 | 1 |
| 18 | Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study | 2011 | 1 |
| 19 | Magnetic resonance imaging assessments of patients with RA and their association with clinical and radiographic outcomes | 2011 | 1 |
| 20 | Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis | 2012 | 1 |
About R Fleischmann
R Fleischmann is a scholar working on Rheumatology, Pharmacology, Urology, Hematology and Psychiatry and Mental health, having authored 21 papers that have together received 731 indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (17 papers), Inflammatory mediators and NSAID effects (2 papers), Osteoarthritis Treatment and Mechanisms (2 papers), Spondyloarthritis Studies and Treatments (2 papers), Autoimmune and Inflammatory Disorders Research (1 paper), Urological Disorders and Treatments (1 paper), Sexual function and dysfunction studies (1 paper) and Vasculitis and related conditions (1 paper). The work is most often cited by research in Rheumatology (392 citations), Immunology (75 citations), Hematology (37 citations), Infectious Diseases (37 citations) and Oncology (39 citations). R Fleischmann has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include Gerd Rüdiger Burmester, Lifen Zhou, Paul E. Emery, Edward Clark Keystone, Philip J. Mease, Bruce W Kirkham, Nora G. Singer, A. Gibofsky, Fabrizio De Benedetti and Thomas Ernst Dorner. Their work appears in journals such as Annals of the Rheumatic Diseases, Lara D. Veeken, Value in Health, Transfusion and Arthritis & Rheumatism.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.